⌕
Protagonist Therapeutics · PTGX · Nasdaq
Tenet 65 · Solid
Compare
$124.67−0.13%At closeTenet 65 · Solid
$124.67−0.16 (−0.13%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Protagonist Therapeutics (PTGX) Stock

Protagonist Therapeutics (PTGX) closed at $124.67 on Nov 17, 2026; its Tenet Score is 65 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

9 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$124.67
Nov 17, 2026
Market cap
$8.1B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
26.2×
TTM through Sep 30, 2026 · as of close, Nov 16, 2026
52-week range
77.00 – 160.81
low → high · as of close, Nov 16, 2026
Tenet Score
65/100
Solid · 340 Healthcare peers

Industry: Drugs

Protagonist Therapeutics Inc scores 65/100. Solid. Strongest on financial health and quality, value is the soft spot, trading at 26× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
65/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
37
Quality
75
Health
90
Growth
59

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueDQualityBHealthAGrowthCMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
7.5×
Sep 30, 2026 balance sheet
P/S
14.8×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
40%
TTM through Sep 30, 2026
Operating margin
−343.6%
fiscal 2025, before interest and tax
Net margin
62.0%
TTM through Sep 30, 2026
Current ratio
19.85
Sep 30, 2026 balance sheet
Net debt / EBITDA
−2.5×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectab…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 149 US ETFs · top wrappers by weightSee all ETFs holding PTGX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Protagonist Therapeutics in?

Protagonist Therapeutics is in the Healthcare sector and the Drugs industry.

What is Protagonist Therapeutics' Tenet Score?

Protagonist Therapeutics' Tenet Score is 65 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.